1-4 of 4
Zheng Xia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Edward C. Dominguez, Carly Roleder, Canping Chen, Zheng Xia, Sandra Wiley, Matthew S. Davids, Alexey Danilov
Journal: Blood
Blood (2024) 144 (Supplement 1): 721.
https://doi.org/10.1182/blood-2024-198693
Published: 2024
Journal Articles

Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)

Tingting Liu, Vi Lam, Elana Thieme, Olga Danilova, Nur Bruss, Lapo Alinari, Jeffrey W. Tyner, Stephen E. Kurtz, Zheng Xia, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 6016–6017.
https://doi.org/10.1182/blood-2022-159691
Published: 2022
Journal Articles

Transcriptional Reprogramming of Super-Enhancer Associated Oncogenes Following Inhibition of Cyclin-Dependent Kinase-9 (CDK9) in Aggressive Non-Hodgkin Lymphoma (NHL)

Elana Thieme, Duanchen Sun, Geeta G Sharma, Nur Bruss, Tingting Liu, Daniel J Coleman, Zheng Xia, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 3493.
https://doi.org/10.1182/blood-2021-149725
Published: 2021
Journal Articles

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

Mustafa Benekli, Zheng Xia, Kathleen A. Donohue, Laurie A. Ford, Lynda A. Pixley, Maria R. Baer, Heinz Baumann, Meir Wetzler
Journal: Blood
Blood (2002) 99 (1): 252–257.
https://doi.org/10.1182/blood.V99.1.252
Published: 2002